A detailed history of D. E. Shaw & Co., Inc. transactions in Royalty Pharma PLC stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 932,340 shares of RPRX stock, worth $24 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
932,340
Holding current value
$24 Million
% of portfolio
0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$25.63 - $29.27 $23 Million - $26.3 Million
898,728 Added 2673.83%
932,340 $26.4 Million
Q2 2024

Aug 14, 2024

BUY
$26.26 - $29.9 $882,651 - $1 Million
33,612 New
33,612 $886,000
Q4 2023

Feb 14, 2024

SELL
$26.21 - $29.22 $10.1 Million - $11.2 Million
-384,459 Reduced 96.64%
13,387 $376,000
Q3 2023

Nov 14, 2023

SELL
$26.26 - $31.38 $755,132 - $902,363
-28,756 Reduced 6.74%
397,846 $10.8 Million
Q2 2023

Aug 14, 2023

BUY
$29.6 - $36.56 $2.86 Million - $3.54 Million
96,782 Added 29.34%
426,602 $13.1 Million
Q1 2023

May 15, 2023

SELL
$32.77 - $39.4 $10.2 Million - $12.2 Million
-310,904 Reduced 48.52%
329,820 $11.9 Million
Q4 2022

Feb 14, 2023

SELL
$39.17 - $44.04 $1.61 Million - $1.81 Million
-41,062 Reduced 6.02%
640,724 $25.3 Million
Q3 2022

Nov 14, 2022

BUY
$39.88 - $44.65 $21.2 Million - $23.7 Million
530,538 Added 350.77%
681,786 $27.4 Million
Q2 2022

Aug 15, 2022

BUY
$37.53 - $44.22 $2.63 Million - $3.09 Million
69,947 Added 86.03%
151,248 $6.36 Million
Q1 2022

May 16, 2022

BUY
$37.46 - $42.44 $3.05 Million - $3.45 Million
81,301 New
81,301 $3.17 Million
Q3 2021

Nov 15, 2021

SELL
$36.14 - $42.24 $1.95 Million - $2.28 Million
-54,095 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$39.85 - $46.63 $2.16 Million - $2.52 Million
54,095 New
54,095 $2.22 Million

Others Institutions Holding RPRX

About Royalty Pharma plc


  • Ticker RPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 437,139,008
  • Market Cap $11.2B
  • Description
  • Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...
More about RPRX
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.